SMO and medulloblastoma: Although our analysis panel included genes previously identified by largescale profiling studies of medulloblastoma, such as CTNNB1 or SMO, it did not include PRDM6 and TERT mutations; however, there are no therapeutics targeted to these alterations at this time, and as such, these have not been included in our focused therapeutic target profiling.